Navigation Links
Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
Date:1/7/2008

SAN FRANCISCO, Jan. 7 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced an update on the company's HCV pipeline, including promising second-generation polymerase and protease inhibitor compounds for the treatment of hepatitis C. This update will be presented on Tuesday, January 8, at 2:30 p.m. PT at the JP Morgan Healthcare Conference in San Francisco, CA.

Second-Generation Nucleoside Polymerase Inhibitor Program

Idenix's preclinical HCV nucleoside polymerase inhibitor program comprises two novel nucleotide prodrugs, IDX184 and IDX102. This program is based on Idenix's proprietary liver-targeting technology, which delivers high levels of nucleoside triphosphate in the liver, potentially maximizing drug efficacy and limiting systemic side effects.

In preclinical studies using an HCV replicon assay, IDX184 exhibited 10 times greater potency than nucleosides currently in clinical development. In a 7-day preclinical toxicology study of IDX184, no toxicities, including gastrointestinal or hematological, were observed in monkeys at doses greater than or equal to 600 mg/kg/day. In HCV genotype-1 infected chimpanzees, once- daily oral administration of 10 mg/kg of either nucleotide prodrug produced a rapid and potent inhibition of HCV replication with mean viral load reductions ranging from 1.5 log(10) with IDX102 to 2.5-4.0 log(10) with IDX184 after 4 days of dosing. IDX184 has been selected as the company's lead candidate from this program and clinical data are expected in 2008.

Novel Macrocyclic Protease Inhibitor Program

Idenix is e
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
4. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... their offering. The Central Nervous System (CNS) ... of pharmaceuticals industry. The numbers of CNS disorders have increased ... to meet the market requirements. There has been steady to ... the past two decades. The market for CNS therapies is ...
(Date:8/29/2014)... DENVER , Aug. 29, 2014 Does your ... date, nearly 800 doctors have recommended marijuana to the over ... Amendment 20. But the majority of the other roughly 20,300+ ... still know very little about it – even though a ... adults say they have tried it. ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... 2012 OPKO Health, Inc. and ChromaDex Corporation (OTCBB: ... alliance pursuant to which ChromaDex has licensed to OPKO ... technologies for distribution and business development throughout all of ... BluScience™ ( www.bluscience.com ), ChromaDex,s recently launched ...
... 2012 Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today announced ... study in the United Kingdom. This large ... up to 20 centers across the UK. Using Uroplasty,s ...
Cached Medicine Technology:OPKO Health, Inc. Invests in ChromaDex® Corp. 2OPKO Health, Inc. Invests in ChromaDex® Corp. 3OPKO Health, Inc. Invests in ChromaDex® Corp. 4OPKO Health, Inc. Invests in ChromaDex® Corp. 5Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC 2Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC 3
(Date:8/29/2014)... US Preventive Services Task Force recommendations for screening and ... may be ameliorated through technological approaches according to a ... published online August 21, 2014 in the Journal ... David Levine, MD, MA, a third year resident in ... colleagues found that compared to usual care, technology-assisted interventions ...
(Date:8/29/2014)... 29, 2014 According to the ... accepting applications next month for medical marijuana, regulators, ... accepting marijuana as a legalized medicine. New marijuana ... be permitted to operate in accordance with local ... best suited to handle legal cannabis. , ...
(Date:8/29/2014)... The microbiology testing sector is one of the ... is also the hugest challenge facing suppliers during these ... of AIDS – still the world’s key health threat ... opportunistic infections (OIs); bioterrorism threat; advancements in technologies for ... Although for certain infections the etiology remains a mystery, ...
(Date:8/29/2014)... 2014 Floors of hospitals and other ... socks. Also, many patients are relegated to lying down ... recovery, Alzheimer’s, etc. Two inventors from Perrysburg, Ohio, have ... safety. , This special pair of socks helps prevent ... patients who are relegated to beds or chairs from ...
(Date:8/29/2014)... 2014 The 8th Annual Paint Columbus Pink® ... a Cause, Pink Pooch Contest, Light of Life Ceremony, Power ... Pink Bow Campaign – all in support of cancer awareness. ... this year…. Paint Columbus Pink Foam and Obstacle Challenge on ... 727 54th Street, Columbus, Georgia 31904. It will be the ...
Breaking Medicine News(10 mins):Health News:Options for weight loss your primary care doctor might not know about 2Health News:Medical Marijuana Approaches Legalization in Chicago 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 3Health News:Paint Columbus Pink Cancer Awareness/Kick-Off Meeting for Anyone Interested in Participating 2
... too much strain on or weaken children,s immune systems ... from the Robert Koch Institute investigate exactly this research ... International (Dtsch Arztebl Int 2011; 108(7): 105-11). Their ... Health Interview and Examination Survey for Children and Adolescents ...
... the early data from Understanding Society based on 14,000 UK ... people with higher levels of education and by married people. ... on sleep, with those in routine occupations reporting worse sleep ... at the University of Surrey who analysed the findings said: ...
... , THURSDAY, March 3 (HealthDay News) -- More than ... a night, which affects their concentration and general health, ... work performance and the ability to drive safely, found ... Prevention (CDC), which published two sleep studies March 4 ...
... combined effects of chemotherapy and endocrine therapy may increase ... In a study scheduled for publication in the April ... Rehabilitation , researchers from the Oregon Health & Science ... survivors whether they had fallen in the past year ...
... , THURSDAY, March 3 (HealthDay News) -- An analysis ... women with breast cancer, a new study reports. Researchers ... breast cancer tumors, and found that the way collagen fibers ... may aid in a patient,s diagnosis and help determine treatment. ...
... , THURSDAY, March 3 (HealthDay News) -- New ... improved sleep treatments, a new study suggests. A team ... as the emblem of wakefulness persists in a hidden form ... -- something that appears to affect people,s vulnerability to being ...
Cached Medicine News:Health News:The better off sleep better 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 3Health News:Breast cancer survivors at higher risk for falls 2Health News:Tissue Analysis May Help Predict Breast Cancer Outcome 2Health News:Particular Brain Rhythm in Sleep Makes You More Vulnerable to Disturbances 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: